Revivicor is at the forefront of xenotransplantation, a groundbreaking approach that involves transplanting organs or tissues between different species, specifically using genetically engineered pigs to address the critical shortage of human organs for transplantation. The company has developed a unique line of pigs, including the GalSafe™ lineage, which has been genetically modified to eliminate the alpha-gal sugar that can trigger immune rejection in human recipients. By editing ten genes in the pig genome, Revivicor aims to create organs that are not only viable for transplantation but also compatible with human biology, thereby reducing the risk of rejection and improving patient outcomes. Their development-stage products, such as UHeart™ and UKidney™, represent scalable solutions for end-stage cardiac and renal diseases, respectively.

To ensure the safety and efficacy of their xenotransplantation products, Revivicor employs advanced precision gene editing techniques and somatic cell nuclear transfer (SCNT) to produce pigs that carry the desired genetic modifications. The company meticulously screens and analyzes these pigs to confirm the integrity of the gene edits before any potential organ transplantation. Additionally, Revivicor raises its organ donor pigs in designated pathogen-free facilities to mitigate the risk of disease transmission to human recipients. With FDA approvals for certain applications, including the use of GalSafe™ pigs for food and therapeutics, Revivicor is paving the way for innovative solutions to alleviate the organ shortage crisis and improve the quality of life for patients in need.

United States

Revivicor Inc.is a regenerative medicine company focused on applying animal biotechnology platforms to provide high-volume, human-compatible, alternative tissue source for treating human degenerative disease. The company produces pig islets, organs, and medical devices aimed at human clinical applications.

Revivicor

Company Details